You are using an unsupported browser.
Some features of this site may not function properly. For optimal user experience, please view this site in Chrome, Firefox, Safari, or Edge.

News Room

Announcements

Date

Announcement

   
April 26, 2019 Repligen Corporation Announces Agreement to Acquire Process Analytics Innovator C Technologies and Reports Preliminary First Quarter 2019 Financial Results. Read More
 
Septermber 4, 2018
 
Sartorius Stedim Biotech and Repligen Corporation Partner to Introduce Next-Generation Perfusion-Enabled Bioreactors. Read More

June 28, 2018

Repligen Selects Purolite Life Sciences as Commercial Partner for New High Performance Ligand.  Read More

June 27, 2018

Repligen Announces Agreement with Navigo Proteins for the Exclusice Co-Development of Next Generation Affinity Ligands.  Read More

June 23, 2017

Repligen Corporation and Spectrum Inc. to Join Forces.  Read More

December 15, 2016

Repligen acquires TangenX Technology Corporation.  Read More

October 4, 2016

Repligen Launches Single-Use XCell™ ATF System for Bioprocess Intensification.  Read More

April 4, 2016

Repligen acquires Atoll GmbH.  Read More

 

In the News

Date

Title

Publication

     
May 20, 2019 OPUS focus: Repligen expands to support chromatography demand Dan Stanton
BioProcess International
August 21, 2018

Fortune Top 100 Fastest-Growing Companies in 2018
Repligen: #74

Fortune Inc.

November 1, 2017

Purolite Selects Repligen's Market-Leading OPUS® Pre-Packed Columns

PR Newswire

October 3, 2017

Balancing the up and downstream: Repligen CEO talks R&D and M&A

Dan Stanton
BioPharma Reporter
June 23, 2017

Repligen agrees to buy Spectrum for $359 milion

Robert Weisman
Boston Globe
March 8, 2017 Repligen to up column production on back of 'milestone year of chromatography' Dan Stanton
BioPharma Reporter
December 20, 2016

Repligen adds single-use filtration technology through TangenX acquisition

Dan Stanton
BioPharma Reporter
December 15, 2016

Repligen pays $40 milion to buy TangenX™ Technology

Robert Weisman
Boston Globe
October 13, 2016

Repligen Launches Single-use Version of its Cell Retention Technology

Dan Stanton
BioPharma Reporter

 


Press Contact

Sondra Newman
Senior Director, Investor Relations

press @ repligen.com

Phone: 781.250.0111
Toll-free: 800.622.2259
Fax: 781.250.0115

download repligen logo